A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules
Condition: Healthy Volunteers
Intervention: 30 mg dexlansoprazole capsules manufactured at TOB; 30 mg dexlansoprazole capsules manufactured at TPC; 60 mg dexlansoprazole capsules manufactured at TOB; 60 mg dexlansoprazole capsules manufactured at TPC
Intervention description: Dexlansoprazole delayed-release capsules.; Dexlansoprazole delayed-release capsules.; Dexlansoprazole delayed-release capsules.; Dexlansoprazole delayed-release capsules.
Intervention MeSH terms: Dexlansoprazole; Lansoprazole
Phase: Phase 1
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 122.0
Sex: All
Minimum age: 18 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Drug therapy

Summary:

      The purpose of this study is to assess the BA of 30 or 60 milligram (mg) dexlansoprazole
      capsule manufactured at TOB (Takeda GmbH Plant Oranienburg) to the corresponding 30 or 60 mg
      dexlansoprazole manufactured at TPC (Takeda Pharmaceutical Company Ltd.).
    

Eligibility criteria:

        Inclusion Criteria:

          1. Has a body mass index (BMI) from 18 to 30 kilogram per square meter (kg/m^2), at
             Screening.

          2. Is willing and able to consume the high-fat/high-calorie breakfast administered during
             the study.

        Exclusion Criteria:

          1. Has a history of drug abuse (defined as any illicit drug use) or drug addiction in the
             12 months prior to Screening or a history of alcohol abuse (defined as regular
             consumption exceeding 21 units per week [1 unit equal (=) 12 ounces (oz) beer, 1.5 oz
             hard liquor, or 5 oz wine]) within 1 year prior to the Screening Visit, or is
             unwilling to agree to abstain from alcohol and drugs throughout the study.

          2. Has a positive test result for drugs of abuse (defined as any illicit drug use) or
             alcohol at Screening or Check-in (Day -1 of Period 1).

          3. Has received any known hepatic or renal clearance altering agents (example,
             erythromycin, cimetidine, barbiturates, phenothiazines, fluvoxamine, etc) for a period
             of 28 days prior to Day 1 of Period 1.

          4. Has donated blood products (such as plasma) within 30 days or has donated whole blood
             or lost 450 milliliter (mL) or more of his or her blood volume, or had a transfusion
             of any blood product within 56 days prior to Day 1 of Period 1.

          5. With the exception of acetaminophen, the subject has taken any excluded medication,
             supplements, or food products or beverages containing grapefruit or grapefruit juice,
             star fruit or star fruit juice, Seville-type (sour) oranges and marmalade, apple,
             orange, or pineapple juice, vegetables from the mustard green family (example, kale,
             broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard), and
             charbroiled meats. Hormonal contraception and hormone replacement therapy are allowed,
             as long as the subject has been on a stable dose for a minimum of 90 days prior to Day
             1 of Period 1.

          6. Has used nicotine-containing products (including but not limited to cigarettes, pipes,
             cigars, chewing tobacco, nicotine patch nicotine gum, e-cigarettes) within 28 days
             prior to Check-in (Day -1 of Period 1), or has a positive cotinine test at Screening
             or Check-in (Day -1 of Period 1), or is unwilling to abstain from these products for
             the duration of the study.

          7. Has received dexlansoprazole or lansoprazole in a previous clinical study or as a
             therapeutic agent within 6 months of screening.